Filip Van den Bosch, MD, described his strategies for caring for patients with SpA and the possibility of achieving disease inactivity.
Search results for: axial spondyloarthritis
Cytokine Targets & Treatment Developments for Psoriatic Arthritis & Spondyloarthritis
ACR CONVERGENCE 2020—In recent years, a pathophysiological role for the interleukin (IL) 17/IL-23 axis in the development of psoriasis, enthesitis and inflammatory arthritis has been investigated in both rodent and human models. Clinical trials have demonstrated differential benefits for skin disease and joint disease in patients with psoriatic arthritis, axial spondyloarthritis (axSpA) and ankylosing spondylitis…
Men, Women & Medical Differences in Axial Spondyloarthropathy
Historically, ankylosing spondylitis was considered mainly a male disease. But it has become evident this predominance is not as great as previously believed. Here we discuss recent developments in the area, including potential differences between the sexes in symptom and disease burden, immunological and genetic background, diagnostic delay, treatment response and ongoing research questions. Medical…
Peripheral Arthritis & Recent Onset Axial SpA: 5-Year Results from the DESIR Cohort
An analysis of follow-up data from the DESIR cohort showed patients with recent onset axial spondyloarthritis who experienced peripheral arthritis had worse symptoms and quality of life long term. In the study, peripheral arthritis was also associated with negative HLAB27, non-smoking and the presence of other peripheral disease manifestations…
Peripheral Manifestations of Spondyloarthritis
A recent study evaluated the factors associated with the presence of peripheral manifestations of spondyloarthritis (SpA), which affects more than half of patients with SpA. Researchers found that being older, HLAB27 negative and having a history of psoriasis were associated with these symptoms…
Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus
Results from a Phase 3 study showed ixekizumab significantly improved the signs and symptoms of non-radiographic axial spondyloarthritis in patients…
FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA
Certolizumab pegol is now FDA approved to treat adults with active non-radiographic axial spondyloarthritis…
Can Peripheral Spondyloarthritis Be Reversed?
Currently, treatment options for patients with peripheral spondyloarthritis, which includes psoriatic arthritis and non-psoriatic types, are limited. Philippe Carron, MD, Department of Rheumatology, Ghent University Hospital, Belgium, says, “One of the problems we encounter in the daily management of peripheral spondyloarthritis is that we have no other therapeutic options in patients refractory to NSAIDs [non-steroidal…
Bone Marrow Edema Studied for Spondyloarthritis Diagnostic Insights
Researchers in Demark studied joints of young adult athletes to better understand the difference in bone marrow edema common in healthy people vs. what is experienced by patients with spondyloarthritis, a serious inflammatory condition of the spine and sacroiliac joints. Early recognition of spondylo-arthritis can be tricky because it can be confused with symptoms and…
2017 Update of Treat-to-Target Recommendations for Axial & Peripheral SpA & PsA
An international task force has updated recommendations for axial and peripheral spondyloarthritis, and psoriatic arthritis, which include treat-to-target recommendations…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 19
- Next Page »